← Back to Search

Stem Cell Therapy

Descartes-30 for ARDS Related to COVID-19

Phase 1 & 2
Recruiting
Research Sponsored by Cartesian Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients must be 18 years of age or older at the time of enrollment
Patient maintains a diagnosis of moderate or severe ARDS according to the Berlin definition of ARDS
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This trialtests the safety of a new treatment for COVID-19 in people with ARDS.

Who is the study for?
This trial is for adults over 18 with moderate or severe ARDS as defined by the Berlin criteria, who also have COVID-19. It's not open to those in other experimental trials or patients expected to live less than 24 hours.Check my eligibility
What is being tested?
The study is testing the safety of a cell therapy called Descartes-30 in patients suffering from acute respiratory distress syndrome (ARDS) exacerbated by COVID-19 infection.See study design
What are the potential side effects?
Since this is an emergency study for a new treatment, specific side effects of Descartes-30 are being investigated and may include typical reactions related to cellular therapies.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
My condition is diagnosed as moderate or severe ARDS.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To assess the safety of Descartes-30 in patients with moderate-to-severe ARDS.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Descartes 30Experimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Cartesian TherapeuticsLead Sponsor
8 Previous Clinical Trials
218 Total Patients Enrolled

Media Library

Descartes-30 (Stem Cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT04524962 — Phase 1 & 2
Coronavirus Research Study Groups: Descartes 30
Coronavirus Clinical Trial 2023: Descartes-30 Highlights & Side Effects. Trial Name: NCT04524962 — Phase 1 & 2
Descartes-30 (Stem Cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04524962 — Phase 1 & 2
Coronavirus Patient Testimony for trial: Trial Name: NCT04524962 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
California
What site did they apply to?
University of California-Irvine
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
1

Why did patients apply to this trial?

This is now the second time I have contracted Covid in the last two years.
PatientReceived no prior treatments
~1 spots leftby May 2024